CSL’s vow to supply Australia with a Covid-19 vaccine if it is made could run into trouble
Stricter US plasma donation rules could cut CSL's earnings 10%
28 October 2020 - 13:13
Sydney — Earlier in 2020, a low-key biomedical firm briefly toppled Australia’s biggest bank and miner to become the country’s most expensive company and a household brand, thanks to its part in the race to produce a Covid-19 vaccine.
But while the coronavirus pandemic has lifted CSL’s investment profile, virus anxieties are also hitting its most lucrative business: taking blood from donors and converting it into medical treatment...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.